NRx Pharmaceuticals Inc (NRXPW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NRx Pharmaceuticals Inc (NRXPW) has a cash flow conversion efficiency ratio of 0.311x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.29 Million) by net assets ($-13.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NRx Pharmaceuticals Inc market cap and net worth for the company's overall valuation and market capitalisation.
NRx Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how NRx Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
NRx Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NRx Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore NRx Pharmaceuticals Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Housing Development and Infrastructure Limited
NSE:HDIL
|
-0.042x |
|
Us1 Critical Minerals Limited
AU:USC
|
-1.463x |
|
Seed Capital Solutions Plc
LSE:SCSP
|
N/A |
|
VIFRANA
RO:BIOW
|
N/A |
|
Ethernity Networks Ltd
LSE:ENET
|
-1.768x |
|
CuriosityStream Inc
NASDAQ:CURIW
|
0.093x |
|
European Resources Limited
AU:ERE
|
N/A |
|
Tarrina Resources Limited
AU:TR8
|
0.092x |
Annual Cash Flow Conversion Efficiency for NRx Pharmaceuticals Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of NRx Pharmaceuticals Inc from 2017 to 2025. View today's stock price for NRx Pharmaceuticals Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-15.94 Million | $-14.11 Million | 0.885x | +93.32% |
| 2024-12-31 | $-23.22 Million | $-10.64 Million | 0.458x | -75.19% |
| 2023-12-31 | $-11.73 Million | $-21.66 Million | 1.846x | +134.40% |
| 2022-12-31 | $7.41 Million | $-39.76 Million | -5.366x | -196.10% |
| 2021-12-31 | $20.81 Million | $-37.70 Million | -1.812x | -3601.91% |
| 2020-12-31 | $-43.77 Million | $-2.27 Million | 0.052x | +292.57% |
| 2019-12-31 | $29.50 Million | $-792.73K | -0.027x | -294.90% |
| 2018-12-31 | $69.54 Million | $-473.19K | -0.007x | -248.09% |
| 2017-12-31 | $69.47 Million | $-135.81K | -0.002x | -- |
About NRx Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone… Read more